[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wound-healing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wound-healing":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,43,86,97,128,161,182,215,247,284,316,350,371,390,406,424,444,473,501,523,551,585,600,628,652],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053273","management-of-abdominal-post-surgical-scar-with-ozoaqua-versus-standard-care-100053273",false,"NCT07678372","Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care","Prospective, Randomized, Evaluator-blinded Clinical Study to Compare a Post-surgical Scar Care Protocol Using OzoAqua Products Versus Standard Care in Open Abdominal Surgery.","Inclusion Criteria:\n\n* Age ≥18 years\n* Scheduled open abdominal surgery\n* Primary wound closure\n* Assessable linear abdominal scar\n* Signed informed consent\n* Ability to complete 3-month follow-up\n\nExclusion Criteria:\n\n* Known allergy to treatment components\n* Active infection or significant dehiscence in the immediate postoperative period\n* Planned use of specific scar treatments -silicone products, laser therapy, local corticosteroids- except as clinical rescue treatment\n* Inability to complete follow-up\n* Participation in another study that may interfere with wound healing","FEMALE","18 Years",{"count":20,"type":21},144,"ESTIMATED","INTERVENTIONAL",[24],"NA","A prospective, randomized clinical study with a blinded evaluator to compare a post-surgical abdominal scar care protocol using Ozoaqua products versus standard care in patients undergoing open abdominal surgery. The primary objective is to assess whether the use of Ozoaqua, initiated in the immediate postoperative period according to wound evolution, improves abdominal scar quality at 3 months compared with usual care.\n\nThe proposed design is an initial single-center study at the Clínica Universidad de Navarra, with 1:1 random allocation to two parallel arms: an intervention group receiving standard care plus Ozoaqua ozonated soap and oil, and a control group receiving standard care only. The primary scar assessment will be performed by a blinded evaluator, while treatment will be open-label due to the nature of the topical intervention.\n\nThe target population consists of adult patients undergoing scheduled open abdominal surgery, with primary wound closure and an assessable linear abdominal scar. Follow-up will be integrated into routine clinical care, including an in-hospital phase during the first postoperative days and outpatient visits at approximately 2 weeks, 1 month and 3 months, with the latter being the main study visit.\n\nThe primary endpoint will be scar quality at 3 months, assessed using the POSAS scale, particularly the blinded observer score. Secondary endpoints will include the patient POSAS score, scar evolution, wound complications, pain, pruritus, satisfaction, cutaneous adverse events, rescue treatments and adherence.",[27,28,29],"Wound Healing","Abdominal Surgery","Scar Improvement","NOT_YET_RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":21},"2026-07-06",{"date":38,"type":21},"2027-07-06",{"name":40,"class":41},"Laboratorios Ozoaqua","INDUSTRY",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":42},"100642443","phase-4-oral-nifedipine-versus-placebo-for-pain-and-healing-after-hemorrhoidectomy-100642443","NCT07659665","Oral Nifedipine Versus Placebo for Pain and Healing After Hemorrhoidectomy","The Effect of Oral Nifedipine Versus Placebo on Postoperative Pain and Healing Following Hemorrhoidectomy in Adult Patients: A Randomized Controlled Trial in Sana'a, Yemen","NIFEDIPINE-HD","Inclusion Criteria:\n\n* Adult patients aged 18-65 years\n* Scheduled for elective hemorrhoidectomy for grade III or IV hemorrhoids\n* Ability to provide written informed consent\n* Ability to understand and complete study questionnaires\n* Willingness to comply with the study protocol and follow-up visits\n\nExclusion Criteria:\n\n* Known hypersensitivity to nifedipine\n* Severe cardiovascular disease (unstable angina, recent myocardial infarction, severe heart failure)\n* Hypotension (systolic blood pressure \\\u003C 90 mmHg)\n* Severe hepatic or renal impairment\n* Pregnancy or breastfeeding\n* Current use of calcium channel blockers or nitrates\n* Emergency hemorrhoidectomy\n* Concurrent inflammatory bowel disease\n* History of anorectal surgery within the past 6 months","ALL","65 Years",{"count":54,"type":21},100,[56],"PHASE4","The goal of this clinical trial is to evaluate whether oral nifedipine reduces postoperative pain and improves wound healing after hemorrhoidectomy in adult patients aged 18-65 years undergoing elective surgery for grade III or IV hemorrhoids in Sana'a, Yemen.\n\nThe main questions it aims to answer are:\n\n* Does oral nifedipine 20 mg twice daily for 14 days reduce postoperative pain compared with placebo?\n* Does oral nifedipine improve wound healing progression and shorten time to complete healing compared with placebo?\n\nResearchers will compare the nifedipine group to the placebo group to see if there is a significant reduction in pain scores, faster wound healing, lower analgesic consumption, and fewer complications.\n\nParticipants will:\n\n* Take either oral nifedipine 20 mg or an identical-looking placebo capsule twice daily for 14 consecutive days, starting 6 hours after surgery.\n* Report pain intensity using a standard 0-10 Visual Analogue Scale at multiple time points during the first 28 days.\n* Attend follow-up visits on postoperative days 7, 14, and 28 for wound healing assessment and safety monitoring.\n* Use rescue analgesia (paracetamol and\u002For diclofenac) as needed for breakthrough pain.",[59,60,27,61],"Hemorrhoids","Postoperative Pain","Analgesia",[63,64,65,66,67,68,69,70,71,72,73,74,75],"Hemorrhoidectomy","Post-hemorrhoidectomy pain","Internal anal sphincter","Anal sphincter spasm","Nifedipine","Calcium channel blocker","Randomized controlled trial","Yemen","Placebo","Visual Analogue Scale","Pain management","Wound healing","Ecchymosis Discharge Approximation score","2026-06-27",{"date":78,"type":34},"2026-07-01",{"date":80,"type":21},"2026-08-01",{"date":82,"type":21},"2026-12-30",{"name":84,"class":85},"Sana'a University","OTHER",{"id":87,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":25,"conditions":90,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":96,"locationsCount":42},"100645079",{"count":20,"type":21},[24],[27,91],"Post-surgical Abdominal Scar After Open Abdominal Surgery","2026-06-25",{"date":78,"type":34},{"date":36,"type":21},{"date":38,"type":21},{"name":40,"class":41},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":42},"100643966","platelet-rich-plasma-versus-standard-care-for-episiotomy-wound-healing-in-postpartum-women-100643966","NCT07669285","Platelet-Rich Plasma Versus Standard Care for Episiotomy Wound Healing in Postpartum Women","Efficacy of Autologous Platelet-Rich Plasma in Enhancing Episiotomy Wound Healing and Reducing Postpartum Perineal Pain: A Prospective Randomized Controlled Trial (PRP-EpiHeal)","PRP-EpiHeal","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Singular pregnancy, at term (≥ 37 weeks of gestation)\n* Vaginal delivery with episiotomy (midline or mediolateral)\n* Signed informed consent to participate in the study\n\nExclusion Criteria:\n\n* Known coagulation disorders or thrombocytopenia (\\\u003C 100,000\u002Fmm³)\n* Severe anemia (hemoglobin \\\u003C 7 g\u002FdL) at the time of delivery\n* Active systemic or local perineal infection at the time of delivery\n* Uncontrolled diabetes mellitus or other significant comorbidities affecting wound healing (e.g., autoimmune disease under immunosuppressive treatment) Third- or fourth-degree perineal laceration (extending to the anal sphincter or rectal mucosa) Refusal to participate or inability to provide informed consent",true,{"count":107,"type":21},200,[24],"This study looks at whether a treatment made from a patient's own blood, called platelet-rich plasma (PRP), can help heal the cut made during childbirth (episiotomy) better than standard care alone.\n\nPRP is prepared by drawing a small blood sample from the patient and spinning it in a centrifuge to concentrate the platelets, which contain natural healing factors. In this study, women who have an episiotomy during vaginal delivery will be randomly assigned to one of two groups: one group will receive a single injection of their own PRP at the wound site right after delivery, and the other group will receive the usual standard wound care. Neither group's care will otherwise differ.\n\nResearchers will follow each woman for 6 weeks after delivery, checking how well the wound is healing using a standard scoring tool (REEDA score), along with pain levels, any complications like infection or wound reopening, and how satisfied participants are with their recovery.\n\nThe goal is to find out whether this simple, low-risk treatment using a woman's own blood can speed up healing and reduce discomfort after childbirth.",[111,112,27,113],"Episiotomy","Platelet Rich Plasma (PRP)","Obstetric",[115,116,117,118,119],"episiotomy","platelet rich plasma","wound healing","obstetric","postpartum period",{"date":121,"type":34},"2026-06-30",{"date":123,"type":21},"2026-06-21",{"date":125,"type":21},"2028-12-30",{"name":127,"class":85},"Saint Andrew Hospital Constanta",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":145,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":42},"100633236","the-application-of-infrared-thermography-in-the-prediction-of-skin-healing-in-surgery-100633236","NCT07524062","The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery","The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery THERMS: THermography for Evaluation of Recovery and Monitoring of Surgical Wounds","THERMS","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Adult subjects (\\>18 years of age) at time of enrolment\n3. Patients undergoing a surgical excision under local anesthesia\n4. Indications of the excisions were skin lesions suspected to be malignant, skin lesions confirmed to be malignant via prior biopsy\n\nExclusion Criteria:\n\n1. Patient has history of pre-existing diabetes type I and II\n2. Patients with pre-existing chronic wound problems\n3. Patients with renal dysfunction,\n4. Patients with venous insufficiency confirmed via radiographic imaging\n5. Patients who received radiotherapy in the affected area in the past\n6. Patients with chronic steroid use in the past (\\> 3 months) or a immunosuppressant medication history\n7. Female who is pregnant",{"count":137,"type":21},120,[24],"This study investigates whether infrared thermography, a harmless and non-invasive thermal camera technique, can help monitor how surgical wounds heal after skin surgery. The goal is to detect wound problems earlier, such as infection or delayed healing, and to support doctors in making timely clinical decisions.",[27,141,142,143,144],"Surgical Wound Infection","Postoperative Complications","Skin Neoplasms","Skin Transplantation",[146,147,148,149,150],"Infrared thermography","Surgical wound healing","Dermatosurgery","Thermal imaging","Wound complications","RECRUITING","2026-06-16",{"date":154,"type":34},"2026-06-18",{"date":156,"type":34},"2026-06-15",{"date":158,"type":21},"2028-10",{"name":160,"class":85},"Universitaire Ziekenhuizen KU Leuven",{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":42},"100586881","silk-bioprotein-as-a-wound-dressing-for-double-incision-mastectomy-100586881","NCT06921148","Silk Bioprotein as a Wound Dressing for Double-Incision Mastectomy","The Utility of Silk Bioprotein as a Wound Dressing in Female-to-Male Double-Incision Mastectomy","Inclusion Criteria:\n\n* Patients over the age of 18 undergoing double-incision bilateral mastectomy for female-to-male gender affirming surgery with the principal investigator.\n* Physicians will be plastic surgeons in the IU Health system\n\nExclusion Criteria:\n\n* Patients with a history of breast cancer.\n* Patients with prior history of breast surgery.\n* Patients with a prior history of radiation to the chest wall\u002Fbreast.\n* Patients with medical comorbidities that predispose to poor wound healing (diabetes, nutritional deficiency, smoking, inflammatory disease, chronic steroid use, immune deficiency, morbid obesity).\n* Patients with a history of documented allergic reaction to Dermabond\u002FPrineo or Silk Bioprotein dressing, or any of the constituents that make up these dressings.\n* Significant acute or chronic medical, neurologic, or illness in the patient that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability to complete the study, and\u002For compromise the objectives of the study.\n* Physicians not in the IU Health system will not be included.",{"count":169,"type":21},50,[24],"This study will investigate the utility of Silk bioprotein, an FDA-approved and readily available post-surgical dressing, as a wound dressing for patients undergoing double-incision mastectomy for female-to-male gender affirmation surgery.",[27],"2026-06-05",{"date":175,"type":34},"2026-06-09",{"date":177,"type":34},"2025-04-30",{"date":179,"type":21},"2028-06-14",{"name":181,"class":85},"Indiana University",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":201,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100639806","nutritional-status-in-adults-with-diabetic-foot-ulcers-100639806","NCT07621770","Nutritional Status in Adults With Diabetic Foot Ulcers","Nutritional Status in Adults With Diabetic Foot in an Outpatient Wound Clinic: A Feasibility and Pilot Study","NutriDFU-P","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosed with diabetes type 1 or type 2\n* Presence of one or more DFUs\n* Receiving treatment in a participating outpatient wound clinic\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Above ankle amputation of the contralateral leg\n* Current treatment with intravenous antibiotics for acute infection.\n* Current hospitalisation for acute surgical management of the foot ulcer\n* Declining or unable to participate in a telephone follow-up interview.\n* Current long-term enteral (tube feeding) or parenteral nutritional support.\n\nExclusion criteria for bioelectrical impedance analysis (BIA)\n\n\\- Presence of a cardiac pacemaker or other implanted electronic device",{"count":191,"type":21},30,"OBSERVATIONAL","This feasibility and pilot study has two aims. The primary aim is to assess the feasibility of collecting clinical, nutritional, and functional data among adults with diabetic foot ulcers (DFUs) who are treated at an outpatient wound clinic. Specifically, the study will evaluate recruitment and inclusion rates, the relevance and clinical utility of selected variables, and assess the completeness and reliability of data collection.\n\nThe secondary aim is to provide a preliminary characterisation of nutritional status, dietary intake, body composition, muscle strength, mobility, and wound-related quality of life, to inform the design and methodology of a future full-scale national study.\n\nDFUs are associated with delayed healing, recurrent infections, reduced quality of life, and increased risk of hospitalization and amputation. These conditions are frequently accompanied by systemic inflammation, impaired circulation, and metabolic disturbances, which may increase nutritional requirements and negatively affect wound healing.\n\nDespite nutrition being recognized as a modifiable factor of ulcer healing, the nutritional status of individuals with DFUs remains insufficiently characterised, and evidence regarding clinically relevant nutritional deficiencies in this population is limited.\n\nParticipants will undergo assessment of height, weight, body composition, handgrip strength, and a 24-hour dietary recall interview during an outpatient clinic visit. Nutritional screening questionnaires and patient-reported measures of appetite, nutritional impact symptoms, mobility, and quality of life will be collected through telephone interviews within one week of the clinical visit.\n\nEligible participants are adults (\\>18 years) who are referred to the outpatient wound clinic with a hard-to-heal foot ulcer. Participants must be able to communicate in Danish or English.",[195,196,197,198,199,200,27],"Diabetic Foot Ulcers (DFU)","Nutrition Assessment","Malnutrition (Calorie)","Ulcer Foot","Dietary Intake Assessment","Bio-Impedance Measurements",[202,203,74,204,205,206],"DFU","Malnutrition","Nutritional assessment","outpatient","hard-to-heal ulcer","2026-05-29",{"date":209,"type":34},"2026-06-02",{"date":209,"type":21},{"date":212,"type":21},"2026-10-30",{"name":214,"class":85},"Hvidovre University Hospital",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":236,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":42},"100596071","negative-pressure-wound-therapy-for-split-thickness-skin-grafting-to-the-lower-leg-after-excision-of-skin-tumour-a-multicentre-randomised-study-100596071","NCT07040683","Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: A Multicentre Randomised Study","Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: The Legs Trial - A Multicentre Randomised Study","LEGS","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing excision of a skin tumour on the lower leg with planned coverage using split-thickness skin grafting (STSG)\n* Eligible procedures include primary excision, secondary excision, or extended excision performed at the same site as a previous tumour surgery\n* Ability to provide written informed consent\n* Ability to comply with postoperative instructions and follow-up visits\n\nExclusion Criteria:\n\n* Inability to follow postoperative instructions due to cognitive impairment, dementia, or significant language barriers\n* Inability to provide informed consent\n* Severe systemic illness, including:\n* Ongoing sepsis\n* Advanced heart failure\n* End-stage renal or liver disease\n* Active chemotherapy within the previous three months\n* Ongoing treatment with immunosuppressive medications, including:\n* Systemic corticosteroids (e.g., prednisone \\>20 mg\u002Fday or equivalent)\n* Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)\n* Antimetabolites (e.g., methotrexate, azathioprine, mycophenolate mofetil)\n* mTOR inhibitors (e.g., sirolimus, everolimus)\n* Biologic therapies (e.g., rituximab, TNF inhibitors, IL-6 inhibitors, IL-1, IL-17, IL-23 inhibitors)\n* Targeted molecular therapies (e.g., JAK inhibitors such as tofacitinib, baricitinib)\n* Other immunosuppressive drugs\n* Previous radiation therapy to the surgical site\n* Presence of severe skin disease affecting the planned graft recipient site (e.g., advanced psoriasis)",{"count":224,"type":21},242,[24],"The goal of this clinical trial is to compare the effect of negative pressure wound therapy (NPWT) versus traditional dressings on the incidence of transplant infection in adult patients undergoing split-thickness skin grafting (STSG) to the lower leg following excision of a skin tumour. The main questions it aims to answer are:\n\nDoes NPWT reduce the incidence of transplant infection within three months after STSG?\n\nDoes NPWT improve secondary outcomes such as graft take, reduce reoperations, complications, and resource use?\n\nResearchers will compare patients treated with NPWT to patients treated with traditional dressings to see if NPWT results in lower infection rates and better clinical outcomes.\n\nParticipants will:\n\nUndergo excision of a skin tumour on the lower leg followed by STSG.\n\nBe randomized to receive either NPWT or traditional dressings applied over the graft.\n\nFollow a structured postoperative care and mobilisation schedule.\n\nAttend follow-up visits at day 5 and day 14 postoperatively and be monitored through medical record review up to three months after surgery.",[144,228,229,230,142,141,231,232,233,27,234,235],"Skin Grafting","Split Thickness Skin Graft","Negative-Pressure Wound Therapy","Lower Extremity","Skin Cancer","Skin Tumour","Bandages","Leg",[144,228,237,230,142,141,231,27,234,235,143,232],"Split Thickness","2026-05-27",{"date":240,"type":34},"2026-05-28",{"date":242,"type":34},"2025-11-01",{"date":244,"type":21},"2030-03-31",{"name":246,"class":85},"Region Skane",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":105,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":42},"100628572","phase-1-study-of-lut017-gel-to-improve-healing-of-skin-wounds-after-removal-of-benign-lesions-in-healthy-adults-100628572","NCT07463378","Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults","A Phase 1, Open-Label Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy Study of a Single Dose of Topically Administered LUT017 Gel for Cutaneous Wound Healing in Volunteers With Healthy Skin","Inclusion Criteria\n\n1. Subjects scheduled to undergo excision of two or more clinically benign skin lesions (e.g., melanocytic nevi or seborrheic keratoses) that will result in at least two comparable acute cutaneous wounds suitable for study treatment.\n2. Subject must be ≥ 18 years of age.\n3. Subjects must be in generally good health, with no dermatologic or systemic condition that may impair normal wound healing, as determined by the Investigator.\n4. Lesions selected for excision must be benign, confirmed clinically by the treating dermatologist or surgeon prior to the procedure.\n5. Must be able and willing to provide informed consent prior to study participation.\n6. Female subjects of childbearing potential must have a negative pregnancy test at day 0. They should agree to use highly effective methods of birth control, defined as those with failure less than 1%, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUD's), sexual abstinence, or a vasectomized partner.\n\nExclusion Criteria\n\n1. Any lesion scheduled for excision that is suspicious for malignancy or has not been clinically assessed as benign by the treating dermatologist or surgeon.\n2. History of abnormal wound healing, including keloid formation, hypertrophic scarring, chronic non-healing wounds, or delayed healing after prior procedures.\n3. Target ulcer shows any signs of infection (only non-infected ulcers are eligible).\n4. Unable to tolerate multi-layer bandages or compression garments.\n5. Decompensated congestive heart failure.\n6. Active soft tissue or bone infection requiring antibiotics.\n7. Skin cancer on the target limb within the last 24 months.\n8. Actively receiving chemotherapy and\u002For radiation therapy for cancer.\n9. Treatment with a serine\u002Fthreonine-protein kinase BRAF inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), BraftoviTM (encorafenib) or Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Day 0, whichever is longer.\n10. Blood chemistry and complete blood count (CBC) values from the most recent laboratory assessment performed within the past 12 monsth:\n\n    1. White Blood Cells (WBC) \\\u003C 1.5 x 109\u002FL.\n    2. Absolute \\\u003C 0.9 x 109\u002FL.\n    3. Platelet count \\\u003C 50 x 109\u002FL.\n    4. Alanine aminotransferase \\> 3 x upper limit of normal.\n    5. Aspartate aminotransferase \\> 3 x upper limit of normal.\n    6. Serum albumin \\\u003C2.0 g\u002FdL.\n11. Current use of systemic corticosteroids \\> 5 mg daily or equivalent within 4 weeks.\n12. Currently pregnant or trying to become pregnant.\n13. Inability or unwillingness to participate in all aspects of study protocol or as determined by the Investigator.\n14. Known hypersensitivity to the ingredients of the study drug.\n15. No known history of diabetis",{"count":255,"type":21},9,[257],"PHASE1","This is a Phase 1 research study evaluating the safety and potential benefits of a topical gel called LUT017 in helping skin wounds heal after minor skin procedures. The study will enroll healthy adults who are already scheduled to have two benign (non-cancerous) skin lesions, such as moles, removed as part of routine care.\n\nWhen the lesions are removed, two small wounds will be created. One wound will be treated with LUT017 gel, and the other will be treated with a placebo gel that does not contain active medication. This allows each participant to serve as their own comparison. The study team will monitor how the wounds heal over approximately one week using clinical evaluation, photographs, and safety assessments.\n\nLUT017 is a topical medication designed to activate natural skin repair pathways and potentially promote faster healing. The main purpose of this study is to determine whether a single application of LUT017 gel is safe and well tolerated when applied to fresh skin wounds, and to look for early signs that it may improve or speed up wound healing compared to placebo.\n\nThe primary question this study aims to answer is: Is LUT017 gel safe when applied to acute skin wounds, and does it show preliminary evidence of improving early wound healing in healthy adults?\n\nParticipants will be followed for about one week after treatment, with blood tests and skin evaluations to monitor for any side effects. The information gathered from this study will help determine whether LUT017 should continue to be developed as a potential treatment to support wound healing.",[27,260],"Acute Skin Wounds",[262,263,264,265,266,27,267,268,269,270,271,272,273,274,275],"LUT017","Topical BRAF Inhibitor","BRAF Inhibition","Paradoxical MAPK Activation","MAPK Pathway","Acute Cutaneous Wounds","Skin Wound Repair","Re-epithelialization","Excisional Wound Model","Benign Skin Lesion Removal","Dermatologic Surgery","Phase 1 Clinical Trial","Topical Drug Administration","Pharmacokinetics","2026-05-26",{"date":207,"type":34},{"date":279,"type":21},"2026-04",{"date":281,"type":21},"2027-02",{"name":283,"class":85},"Antoni Ribas",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":301,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":42},"100636878","intraoperative-application-of-cold-atmospheric-plasma-to-prevent-postoperative-wound-complications-in-the-inguinal-region-of-high-risk-patients-with-peripheral-arterial-occlusive-disease-100636878","NCT07571408","Intraoperative Application of Cold Atmospheric Plasma to Prevent Postoperative Wound Complications in the Inguinal Region of High-risk Patients With Peripheral Arterial Occlusive Disease","Prophylactic Application of Cold Atmospheric Plasma to Reduce Postoperative Wound Healing Disorders in the Inguinal Region in High-risk Patients With Peripheral Arterial Occlusive Disease- Intraoperative Application of Cold Atmospheric Plasma in the Inguinal Region","PICPAD","Inclusion Criteria:\n\n* Age \\> 18 years\n* Written informed consent\n* Surgical treatment of peripheral arterial occlusive disease (PAOD) with femoral (inguinal) access\n* High-risk patient for wound healing complications:\n\nWHD (wound healing disorder) score ≥ 4 points:\n\nDiabetes mellitus (2) Immunosuppression\u002Fsteroid therapy (2) End-stage renal disease (2) Reinterventions (2) Peripheral arterial occlusive disease (1) Nicotine abuse (1) Obesity (BMI \\> 30) (1) Age \\> 80 years (1) Duration of surgery \\> 4 h (1) Blood loss \\> 1.5 L (1) Local radiotherapy\u002Fchemotherapy (1)\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Femoral access for an indication other than PAOD\n* Preoperative local infection or infectious skin disease\n* Life expectancy \\\u003C 3 months\n* Active infection of the ipsilateral extremity requiring systemic antibiotic therapy at the time of surgery\n* Systemic antibiotic therapy at the time of surgery\n* Use of coated incisional drapes (e.g., iodine-impregnated)\n* Intraoperative use of anti-infective topical agents (e.g., Gentacoll, doxycycline, etc.)\n* Use of fibrin sealants\u002Fthrombogenic adhesive substances above the fascia Planned postoperative prophylactic negative pressure wound therapy (NPWT)",{"count":293,"type":21},214,[24],"The goal of this clinical trial is to learn if postoperative wound complications in the inguinal region of high-risk patients with peripheral arterial occlusive disease can be prevented by the intraoperative application of cold atmospheric plasma.\n\nThe main questions it aims to answer are:\n\nDoes the intraoperative application of cold atmospheric plasma reduce the need for surgical revision of inguinal wounds due to wound healing complications within 3 months postoperatively? Does the intraoperative application of cold atmospheric plasma reduce wound healing complications not requiring revision within 3 months postoperatively?\n\nResearchers will compare the application of cold atmospheric plasma to a placebo (a deactivated look-alike device).\n\nParticipants will:\n\nUndergo surgical treatment with femoral artery access due to their peripheral arterial occlusive disease, in accordance with the respective vascular surgery department standard of care.\n\nReceive a single application of cold atmospheric plasma or, respectively, placebo in the area of their inguinal access wound during surgery (after subcutaneous closure and prior to skin closure).\n\nBe regularly assessed for wound healing during the first postoperative 14 days as part of routine clinical care and undergo a final evaluation at 3 months. They will also be surveyed regarding their quality of life.",[297,27,298,299,300],"Peripheral Occlusive Disease","Wound Healing Complication","Cold Atmospheric Plasma","Prevention",[302,303,304,305,306],"cold atmospheric plasma","prevention","wound healing disorder","vascular surgery","peripheral occlusive disease","2026-05-04",{"date":309,"type":34},"2026-05-06",{"date":311,"type":21},"2026-11-01",{"date":313,"type":21},"2029-06-01",{"name":315,"class":85},"Ursula Werra",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":105,"sex":51,"minAge":323,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":22,"phases":327,"briefSummary":328,"conditions":329,"keywords":333,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":4},"100636711","patient-reported-outcomes-of-four-intraoral-suture-materials-100636711","NCT07569237","Patient-Reported Outcomes of Four Intraoral Suture Materials","Patient-Reported Outcomes Following Application of Intraoral Sutures: A Split-Mouth Randomized Controlled Trial","Inclusion Criteria:\n\nAdults aged 20-30 years.\n\nSystemically healthy (ASA I-II).\n\nNo history of allergy to study suture materials.\n\nPeriodontally healthy, with no active oral lesions, including carious lesions.\n\nDental Requirements: All maxillary canine, second premolar, and first molar teeth present.\n\nMinimal (≤0.5 mm) open contacts between the pairs of teeth that define the study sites.\n\nIdeally, full maxillary dentition present from first molar to first molar.\n\nAt least 2 mm of keratinized tissue width on buccal intervention sites.\n\nWilling and able to provide informed consent.\n\nWilling and able to attend all study follow-up visits and complete study questionnaires.\n\nExclusion Criteria:\n\nAllergy to any study materials (e.g., suture materials or anesthetics) or medications (Paracetamol).\n\nAny systemic disease affecting wound healing (e.g., diabetes, immunosuppression).\n\nUse of any medications.\n\nPregnancy or lactation.\n\nUnwillingness or inability to provide informed consent.\n\nUnwillingness or inability to comply with study protocol and follow-up visits.\n\nExit Criteria:\n\nParticipants may exit the study at any time if they wish to discontinue participation.\n\nNoncompliance with study protocol and visits.\n\nDevelopment of conditions (e.g., infection) that require immediate care or that introduce exclusion criteria.","20 Years","30 Years",{"count":326,"type":21},60,[24],"When patients undergo minor oral surgery, dentists use various types of stitches (sutures) to help the gums heal. These stitches can be made of different materials, and some might feel more comfortable, cause less pain, or interfere less with eating and speaking than others.\n\nThe purpose of this study is to compare four commonly used dental suture materials to see which ones patients prefer. Participants in this study will receive four different types of stitches in different areas of their upper jaw after a routine dental procedure.\n\nPatients will be asked to report their levels of pain, discomfort, and any difficulties with daily activities like eating and talking on Days 3, 7, and 14 after the procedure. A panel of dental specialists will also examine photos of the healing process to see if one material helps the mouth heal better than others. This research will help dentists choose the best materials to improve patient comfort after oral surgery.",[330,27,331,332],"Suture Materials","Patient Comfort","Oral Health-Related Quality of Life",[334,335,336,337,338,339,340,341],"Split-mouth design","Patient-reported outcome measures (PROMs)","Intraoral sutures","Dental surgery","Visual Analog Scale (VAS)","Periodontology","Oral surgery healing","Braided vs Monofilament sutures","2026-04-28",{"date":309,"type":34},{"date":345,"type":21},"2026-07",{"date":347,"type":21},"2028-04",{"name":349,"class":85},"University of Jordan",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":357,"targetDuration":359,"studyType":192,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":4},"100635648","cell-suspension-with-biologic-dressing-for-burn-wounds-100635648","NCT07555418","Cell Suspension With Biologic Dressing for Burn Wounds","A Prospective, Multicenter, Real-World Observational Study of Autologous Epidermal Cell Suspension Combined With Biological Dressing for Wound Repair After Dermabrasion or Surgical Debridement in Patients With Second-Degree Burns","Inclusion Criteria:\n\n* Patients with second-degree burn wounds requiring surgical dermabrasion or debridement and wound repair.\n* Age (No age restriction). For minors under 18 years, informed consent must be provided by a parent or legal guardian.\n* Stable vital signs and able to tolerate debridement and surgical procedures as confirmed by routine examinations.\n* Understand and willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Severe uncontrolled systemic disease or acute systemic infection, or severe organ dysfunction (heart, lung, brain, etc.).\n* Psychiatric disorder that prevents compliance with treatment or follow-up.\n* Known allergy to porcine-derived materials or any component of the cell suspension preparation reagents.\n* Presence of diseases (e.g., autoimmune disease) or use of medications (e.g., high-dose immunosuppressants or corticosteroids) that may significantly affect wound healing.\n* HIV positivity, clinical diagnosis of AIDS, or absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmm³ during screening.",{"count":358,"type":21},386,"6 Months","This study is a prospective, multicenter, real-world observational study. It aims to evaluate the effectiveness and safety of a combined therapy-autologous epidermal cell suspension followed by biological dressing (porcine xenograft) coverage-for wound repair after dermabrasion or surgical debridement in patients with second-degree burns. A total of 193 patients receiving the combined therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 193 matched patients who received conventional treatment alone (e.g., xenograft alone, autologous skin grafting, or standard dressing changes). The primary outcomes include wound healing rate at 4 weeks and time to complete wound closure. Secondary outcomes include scar assessment, pigmentation, functional recovery, quality of life, and safety. Patients will be followed for up to 6 months.",[27],"2026-04-24",{"date":364,"type":34},"2026-04-29",{"date":366,"type":21},"2026-05-01",{"date":368,"type":21},"2029-12-31",{"name":370,"class":85},"First Affiliated Hospital, Sun Yat-Sen University",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":105,"sex":17,"minAge":18,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":42},"100636096","clinical-observational-study-on-changes-in-skin-physiological-parameters-following-ablative-and-non-ablative-fractional-laser-treatment-at-different-doses-100636096","NCT07561242","Clinical Observational Study on Changes in Skin Physiological Parameters Following Ablative and Non-Ablative Fractional Laser Treatment at Different Doses","Inclusion Criteria:\n\n* Female Chinese study participants aged 18 to 60 years (inclusive).\n* Fitzpatrick skin phototypes III, IV, or V.\n* Willing to receive non-ablative fractional laser (M22) and ablative fractional laser (CO2) irradiation on the test sites during the study.\n* No primary or secondary lesions (such as scars, ulcers, vesicles, tattoos) on the test sites.\n* Has not participated in any other studies involving the test area (forearms) in the past 2 months.\n* Agrees not to use skin-whitening products on the test area during the study period.\n* In good general health at the time of the study.\n* Volunteers to participate and signs the informed consent form and photo release authorization.\n* Willing to comply with all requirements of the study.\n\nExclusion Criteria:\n\n* Study participants with skin diseases or skin allergies in the test area.\n* Presence of moderate to severe inflammatory skin diseases (e.g., active eczema, acute photosensitive dermatitis, etc.) on the test sites within the past 4 weeks, or those who require treatment with oral or topical corticosteroids or immunosuppressants for skin conditions.\n* On the day of the visit, the investigator judges the presence of significant diffuse erythema, desquamation, or exudation in the test area that may significantly affect skin color measurement.\n* The investigator assesses that the participant is currently suffering from a stable or progressively worsening disease.\n* Participant is planning for pregnancy, is pregnant, or is breastfeeding (applicable to female participants only).\n* Participant with immunodeficiency.\n* Participant has a history of photosensitivity or photoallergy.\n* Participant has a history of skin cancer or malignant melanoma.\n* Presence of significant scars, tattoos, surgical incisions, or pigmented lesions (e.g., prominent birthmarks) in the test area that may affect assessment, and in the investigator's judgment, would impede normal imaging or scoring.\n* Has used high-potency active products containing high concentrations of retinoic acid\u002Fretinol, alpha hydroxy acids, salicylic acid, etc., on the test area frequently (≥3 times per week) for an extended period (≥4 weeks) within the past 3 months, which, in the investigator's judgment, may significantly affect skin texture or barrier status.\n* History of moderate to severe sun exposure (e.g., prolonged outdoor work, travel to seaside\u002Fhigh altitude) within the past 4 weeks, resulting in significant tanning or sunburn in the test area that, in the investigator's judgment, may interfere with study-related readings.\n* Participation in other clinical or consumer testing projects involving the skin condition of the test area within the past 4 weeks.\n* Presence of significant mental or cognitive impairment affecting compliance, and the investigator considers the participant unable to understand the study procedures or complete the tests as required.","60 Years",{"count":379,"type":21},20,"This clinical observational study investigates the dose-response relationship between laser energy intensity and skin damage\u002Frepair by applying different parameter sets of fractional ablative (CO2) and non-ablative (M22) lasers to the inner forearms of approximately 20 healthy Chinese female volunteers (aged 18-60, Fitzpatrick skin types III-V) in a single-center, self-controlled design. Each participant receives both laser types on contralateral arms, with four distinct energy\u002Fdensity combinations per laser applied to separate test areas, and the dynamic skin responses are evaluated at baseline, immediately post-treatment, and at 30 minutes, 1, 2, 3, 4 hours, 7 days, and 10 days thereafter through clinical assessments (edema, erythema, etc.), standardized photography, high-frequency ultrasound (Dermascan), and objective instrumental measurements of skin color (Chromameter CM26dG), melanin\u002Fhemoglobin (Mexameter MX18), and barrier function (TEWL via Vapometer). The collected data will be analyzed using descriptive and comparative statistical methods to characterize the acute injury and recovery profiles, aiming to establish a foundational model for future post-procedure cosmetic intervention research.",[382,27],"Skin Barrier Function",{"date":366,"type":34},{"date":385,"type":34},"2026-03-21",{"date":387,"type":21},"2026-04-30",{"name":389,"class":41},"ChinaNorm",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":397,"targetDuration":359,"studyType":192,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":404,"leadSponsor":405,"locationsCount":4},"100635330","basement-membrane-regeneration-for-wound-repair-100635330","NCT07551284","Basement Membrane Regeneration for Wound Repair","A Prospective, Multicenter, Real-World Observational Study of Autologous Basement Membrane Regeneration Technology (Epidermal Basal Cell Suspension Using Cell Sorting System) for Wound Repair in Patients Undergoing Skin Grafting, Flap Surgery, or Primary Suture","Inclusion Criteria:\n\n* Patients with wounds requiring surgical repair (skin grafting, flap surgery, or primary suture), including but not limited to: burn wounds, traumatic wounds, post-surgical excision defects (e.g., scars, pigmentation disorders, skin tumors), and chronic wounds (diabetic ulcers, venous ulcers, pressure injuries, radiation ulcers, neuropathic ulcers, burn residual wounds, etc.).\n* Age (No age restriction). For minors under 18 years, informed consent must be provided by a parent or legal guardian.\n* Stable vital signs and able to tolerate surgery as confirmed by routine examinations.\n* Understand and willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Severe uncontrolled systemic disease or acute systemic infection, rapidly progressive or advanced disease, or severe organ dysfunction (heart, lung, brain, etc.).\n* Psychiatric disorder.\n* Presence of diseases (e.g., malignant tumor, autoimmune disease) or use of medications (e.g., high-dose corticosteroids: ≥40 mg prednisone or equivalent per day for ≥2 weeks) that may affect wound healing.\n* HIV positivity, clinical diagnosis of AIDS, or absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmm³ during screening.\n* Pregnancy or breastfeeding.\n* Active infection or necrosis of the wound (unless controlled after debridement).",{"count":398,"type":21},1000,"This study is a prospective, multicenter, real-world observational study. It aims to evaluate the effectiveness and safety of autologous basement membrane regeneration technology (epidermal basal cell suspension prepared using a cell sorting system) for wound repair in patients undergoing skin grafting, flap surgery, or primary suture. A total of 500 patients receiving the cell suspension therapy combined with standard surgical procedures will be enrolled from multiple hospitals across China. Their outcomes will be compared with 500 matched patients receiving standard surgical procedures alone (e.g., skin grafting, flap surgery, or suture without cell suspension). The primary outcomes include complete wound healing rate at 4 weeks (for grafted wounds) and time to complete wound closure (for sutured or flap-repaired wounds). Secondary outcomes include wound area reduction rate, recurrence rate, scar assessment (Vancouver Scar Scale), pain score (ASA), sweat function test, basement membrane integrity (histopathology with collagen IV and VII staining if clinically indicated), and safety. Patients will be followed for up to 6 months.",[27],"2026-04-23",{"date":364,"type":34},{"date":366,"type":21},{"date":368,"type":21},{"name":370,"class":85},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":413,"targetDuration":359,"studyType":192,"phases":4,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":4},"100635123","plasma-therapy-for-scar-management-100635123","NCT07548593","Plasma Therapy for Scar Management","A Prospective, Multicenter, Real-World Observational Study of a Plasma Device for the Treatment of Hypertrophic Scars, Keloids, Atrophic Scars, Postoperative Scars, and Burn Scars","Inclusion Criteria:\n\n* Clinical diagnosis of scar requiring therapeutic intervention, including but not limited to hypertrophic scar, keloid, atrophic scar, postoperative linear scar, burn scar, post-traumatic scar, or post-acne scar.\n* Scar duration ≥ 3 months, in stable or proliferative phase.\n* Age ≥ 12 years (for minors under 18 years, informed consent must be provided by a parent or legal guardian).\n* Stable vital signs and able to tolerate scar treatment.\n* Understand and willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Active infection, ulceration, or malignant tumor involving the scar area. Severe uncontrolled systemic disease or major organ dysfunction (heart, lung, brain, etc.).\n* Psychiatric disorder that prevents compliance with treatment.\n* Presence of diseases (malignant tumor, autoimmune disease) or use of medications (high-dose corticosteroids: ≥40 mg prednisone or equivalent per day for ≥2 weeks) that may affect scar healing or assessment.\n* HIV positivity, clinical diagnosis of AIDS, or absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmm³ during screening.\n* Pregnancy or breastfeeding.\n* Previous treatment of the scar area (e.g., laser, injection, surgery) without a washout period of ≥3 months.",{"count":414,"type":21},800,"This study is a prospective, multicenter, real-world observational study. It aims to evaluate whether adding plasma device therapy to standard scar care is effective and safe for treating various types of scars, including hypertrophic scars, keloids, atrophic scars, postoperative scars, burn scars, and post-traumatic scars. A total of 400 patients receiving standard scar care plus plasma therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 400 matched patients who received standard scar care alone. The main outcomes include change in Vancouver Scar Scale (VSS) score, pruritus relief, pain relief, scar thickness reduction, patient satisfaction, recurrence rate at 6 months, and any side effects. Patients will be followed for up to 6 months after treatment completion.",[27],"2026-04-22",{"date":419,"type":34},"2026-04-27",{"date":366,"type":21},{"date":422,"type":21},"2026-12-31",{"name":370,"class":85},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":431,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":441,"leadSponsor":442,"locationsCount":4},"100634898","periosteal-distraction-with-skin-grafting-for-dfu-100634898","NCT07545668","Periosteal Distraction With Skin Grafting for DFU","Periosteal Distraction Combined With Skin Grafting for the Treatment of Diabetic Foot Ulcers: A Prospective, Randomized, Controlled Study","Inclusion Criteria:\n\n* Age ≥18 years on the day of signing informed consent.\n* Diagnosed with type 2 diabetes mellitus.\n* Diabetic foot ulcer persisting for ≥2 weeks.\n* Wagner grade 2 or 3; or post-amputation (Wagner grade 4-5) wound requiring skin grafting.\n* Wound area ≥3 cm².\n* Brachial-ankle index between 0.71 and 1.30.\n* Hemodynamically stable with routine examinations indicating tolerance to surgery.\n* Mentally competent, able to follow medical advice, and willing to attend scheduled follow-up visits.\n* Understand and voluntarily sign informed consent to participate in this trial.\n\nExclusion Criteria:\n\n* Poorly controlled hyperglycemia (e.g., HbA1c \\>12.0%).\n* Immunosuppression due to underlying disease, long-term immunosuppressive therapy, or high-dose glucocorticoids (e.g., ≥40 mg prednisone or equivalent daily for ≥2 weeks) during screening.\n* Preexisting conditions affecting wound healing (e.g., malignancy, autoimmune disease).\n* Severe uncontrolled systemic disease or acute systemic infection; concomitant severe cardiac, pulmonary, or cerebral disease.\n* Psychiatric disorders.\n* Deemed unsuitable for inclusion by the investigator.\n* Pregnancy, unwillingness to use adequate contraception in women of childbearing potential, lactation, or planning pregnancy within 1 month after study completion.\n* Active osteomyelitis in the target ulcer without adequate debridement and\u002For antibiotic treatment.\n* Significant uncorrected biomechanical deformity expected to severely affect graft survival and function.\n* Active bleeding or significant coagulation abnormality.\n* Previous participation in this study at any time.","85 Years",{"count":433,"type":21},104,[24],"This study is a single-center, prospective, randomized controlled trial aimed at evaluating whether periosteal distraction combined with autologous split-thickness skin grafting can significantly improve graft survival rate at postoperative day 14 compared with skin grafting alone in patients with diabetic foot ulcers (Wagner grade 2-3 or post-amputation). A total of 104 eligible patients will be randomly assigned to either the experimental group (periosteal distraction + skin grafting, n=52) or the control group (skin grafting alone, n=52). Secondary outcomes include time to complete epithelialization, wound healing quality (BWAT score at 3 months), ulcer recurrence rate (at 6 months), foot function (AOFAS score), quality of life (DFS-SF score), and safety profile. This study aims to address the critical clinical bottleneck of poor graft survival in ischemic wound environments, providing a novel, minimally invasive, and synergistic treatment paradigm for diabetic foot ulcers.",[437,27],"Diabetic Foot Disease","2026-04-21",{"date":417,"type":34},{"date":366,"type":21},{"date":368,"type":21},{"name":443,"class":85},"Hu Zhicheng",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":453,"conditions":454,"keywords":459,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":42},"100613189","diep-flap-breast-reconstruction-perioperative-biomarkers-and-outcomes-100613189","NCT07263347","DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes","Prospective Observational Study of Perioperative Biomarkers and Outcomes in Deep Inferior Epigastric Perforator (DIEP) Flap Breast Reconstruction","Inclusion Criteria:\n\n1. Female, 18-70 years old.\n2. Clinically diagnosed with breast cancer and scheduled for immediate DIEP free-flap breast reconstruction after mastectomy.\n3. Conscious and able to understand and voluntarily sign written informed consent.\n\nExclusion Criteria:\n\n1. Severe cardiac, hepatic, or renal dysfunction or severe coagulopathy (e.g., NYHA class III-IV, Child-Pugh class C, eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n2. Preoperative active infection, autoimmune disease, or long-term use of immunosuppressants\u002Fanti-inflammatory drugs (e.g., corticosteroids).\n3. Pregnant or breastfeeding.\n4. Prior ipsilateral breast surgery or radiotherapy that may affect local blood circulation assessment.\n5. Any condition deemed unsuitable by the investigator (e.g., poor compliance).","70 Years",{"count":191,"type":21},"Brief Summary This observational study will follow patients who undergo DIEP flap breast reconstruction to better understand a common surgical challenge called ischemia-reperfusion (I\u002FR) injury. I\u002FR injury can happen when a flap has a period without blood flow (ischemia) and then blood flow returns (reperfusion). This process may trigger inflammation and oxidative stress and is associated with fat necrosis or partial flap loss.\n\n1\\. What is being studied\n\n1. The investigators will measure inflammation and oxidative stress markers in blood (for example, interleukin-6 \\[IL-6\\]) from before surgery through the first 72 hours after surgery.\n2. These data will help map the normal and abnormal patterns of recovery after surgery and may inform future approaches to monitoring and protecting flap tissue.\n3. No experimental drug or device is given to participants in this study. Separate animal studies are developing a near-infrared imaging and antioxidant nanomaterial (Mn\u002FQD-SAC); this is not used in participants here.\n\n2\\. Who can take part\n\n1. Women aged 18-70 scheduled for immediate DIEP flap breast reconstruction after breast cancer surgery.\n2. Key exclusions include severe heart, liver, or kidney disease; significant clotting problems; active infection or autoimmune disease; long-term use of immunosuppressants\u002Fanti-inflammatory drugs; pregnancy or breastfeeding; or other reasons judged by the research team.\n\n3\\. What will happen if you join\n\n1. After providing informed consent, participants will have blood drawn at five time points: pre-operative baseline (within 24 hours before surgery) and at 0, 6, 24, and 72 hours after surgery (about 10 mL each time; total \\~50 mL).\n2. Blood will be processed and stored under secure conditions and tested for inflammation and oxidative stress markers.\n3. The investigators will also record routine clinical information from the medical record (such as age, BMI, surgery duration, ischemia time, and clinical assessments of flap outcomes and complications).\n4. Participation does not change the participant's clinical care before, during, or after surgery.\n\n4\\. Risks and benefits\n\n1. Risks are those of standard blood draws: brief pain, bruising, bleeding, dizziness, and rare infection.\n2. There is no direct medical benefit to participants. Results may help improve understanding and future care for patients undergoing flap reconstruction.\n\n5\\. Privacy and data protection\n\n1. Samples and data will be coded without names. Identifying information is stored separately with restricted access.\n2. Research results are not routinely added to the medical record or returned to participants unless a finding has clear, actionable clinical significance and is approved by the ethics committee.\n\n6\\. Time commitment and costs\n\n1. All blood draws occur during the routine hospital stay. There is no additional follow-up required after discharge.\n2. There is no cost to participate.\n\n7\\. Voluntary participation Joining the study is voluntary. Participants may withdraw at any time without affecting their medical care.",[455,456,142,27,457,458],"Breast Neoplasms","Ischemia-Reperfusion Injury","Oxidative Stress","Inflammation",[460,461,462,463],"Deep inferior epigastric perforator (DIEP) flap","Autologous breast reconstruction","Free tissue transfer","Ischemia-reperfusion injury","2026-04-01",{"date":466,"type":34},"2026-04-03",{"date":468,"type":34},"2025-12-20",{"date":470,"type":21},"2026-10",{"name":472,"class":85},"Hubei Cancer Hospital",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":51,"minAge":480,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":42},"100564811","phase-2-evaluating-rhpdgf-bb-enhanced-wound-matrix-for-head-and-neck-reconstruction-100564811","NCT06634030","Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction","A Randomized, Double-Blinded, Controlled Trial Evaluating Recombinant Human Platelet-Derived Growth Factor B (rhPDGF-BB)-Enhanced Wound Matrix in the Reconstruction of Full-Thickness Head or Neck Defects Following Skin Cancer Excision","Inclusion Criteria:\n\n* Underwent surgery to completely remove skin cancer, either Mohs micrographic or wide local excision, that left a full-thickness surgical defect of the head or neck measuring between 1.5-10cm in greatest dimension with clear margins as assessed in the pathology report.\n* Margins of the wound cannot be approximated or closed with stitches, sutures, staples, or glue\n* Surgeon does not plan for immediate skin graft or flap\n* Aged \\>21 years old\n* Willing and able to provide informed consent for study participation and compliance with study protocol\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Medical conditions that would, in the opinion of the Investigator or treating provider, compromise the safety of the individual with study participation and\u002For the ability of the individual to follow study protocol\n* The device will not fit the contour of the base of the wound bed\n* Evidence of current clinical infection as demonstrated by the invasion of bacteria into the healthy viable tissue on the periphery of the wound (colonization of wound bed due to normal flora or environment is not exclusionary)\n* Prior radiation therapy at the application site\n* Known allergic reactions to porcine tissue, porcine collagen, or yeast-derived products\n* Currently enrolled in a drug or device trial or within 30 days of last investigational drug or device administration at baseline visit where investigational treatment (drug or device) was placed in wound bed or may potentially interact with study treatment\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial","22 Years",{"count":482,"type":21},40,[484],"PHASE2","Skin cancers such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma lesions that develop on the head and neck are treated by Mohs surgery or wide local excision to remove all tumor cells and preserve the normal tissue. These surgical techniques may result in large defects requiring reconstruction to restore function and aesthetics. Rotational flaps and free flaps are techniques used to reconstruct large, complex defects that cannot be closed with sutures, staples, or glue. Older, frail patients are particularly vulnerable to complications from these procedures often leaving them to care for chronic wounds until a skin graft can be placed. Phenome-wide association studies (PheWAS) revealed a cohort of patients with a single nucleotide variant (SNV) in PDGFRβ having a higher incidence of chronic skin ulcers, skin grafts, and other skin and connective tissue disorders suggesting that the loss of PDGFβ signaling may impair healing following trauma. rhPDGF-BB, a recombinant human platelet derived growth factor protein-based therapy, signals through PDGFRβ to mediate inflammation, granulation, angiogenesis, and remodeling during wound healing and skin repair and is FDA cleared for diabetic neuropathic ulcers and periodontal bone and soft tissue reconstructions. These data suggest rhPDGF-BB may be a viable therapeutic strategy to augment the reconstruction of these complex defects by accelerating granulation, epithelialization, and wound closure.",[27,487],"Surgical Wound",[489,490,491],"Complex Surgical Defect","Skin Cancer Excision","Platelet-Derived Growth Factor","2026-03-18",{"date":494,"type":34},"2026-03-23",{"date":496,"type":34},"2025-04-01",{"date":498,"type":21},"2026-06",{"name":500,"class":85},"Vanderbilt University Medical Center",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":52,"enrollmentInfo":507,"targetDuration":4,"studyType":22,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":4},"100628010","effectiveness-of-chlorhexidine-impregnated-gauze-versus-povidone-iodine-dressing-in-post-trauma-wound-care-100628010","NCT07456072","Effectiveness of Chlorhexidine Impregnated Gauze Versus Povidone Iodine Dressing in Post Trauma Wound Care","Inclusion Criteria:\n\n* Patients 18-65 years of age with acute post-trauma wounds.\n* Wounds that are clean contaminated at presentation.\n\nExclusion Criteria:\n\n* Patients with the known allergies to Chlorhexidine or Povidone-Iodine.\n* Chronic wounds or those with underlying chronic conditions, such as diabetes.\n* Patients with compromised immune systems.\n* Pregnant females",{"count":508,"type":21},176,[24],"To compare rate of infection and wound healing between chlorhexidine impregnated paraffin gauze and dry povidone-iodine dressings in post-traumatic wounds.",[512,27],"Wound Infection Post-Traumatic","2026-03-03",{"date":515,"type":34},"2026-03-06",{"date":517,"type":21},"2026-03-01",{"date":519,"type":21},"2026-05-31",{"name":521,"class":522},"Pakistan Institute of Medical Sciences","OTHER_GOV",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":532,"briefSummary":533,"conditions":534,"keywords":537,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":549,"locationsCount":42},"100622388","safety-and-efficacy-of-ntp-in-thyroid-surgery-pilot-study-on-morbidity-prevention-and-adjuvant-oncological-control-100622388","NCT07382973","Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control","Evaluation of Non-Thermal Plasma as an Innovative Strategy for Optimizing Post-Surgical Wound Treatment in Patients of Thyroid Surgery: An Ethical and Clinical Approach","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Diagnosis of thyroid pathology requiring total or subtotal thyroidectomy.\n* Signed Informed Consent Form (ICF).\n* Patients capable of complying with the 12-week follow-up schedule.\n\nExclusion Criteria:\n\n* History of previous neck surgery or radiation therapy in the cervical area.\n* Known history of keloid formation or hypertrophic scarring.\n* Presence of active systemic or local infection at the time of surgery.\n* Patients with implanted electronic devices (e.g., pacemakers or defibrillators) due to the use of RF-based plasma.\n* Pregnancy or breastfeeding.\n* Concurrent use of systemic corticosteroids or immunosuppressive drugs that may impair wound healing.",{"count":531,"type":21},26,[24],"The goal of this clinical trial is to evaluate the therapeutic efficacy and safety of non-thermal plasma (NTP) as an adjuvant treatment for surgical bed decontamination and accelerated tissue repair in patients undergoing total thyroidectomy. The study aims to address the following objectives:\n\n* Does the intraoperative application of NTP to the surgical bed and closed incision promote accelerated tissue regeneration compared to conventional postoperative care?\n* Does NTP treatment reduce postoperative inflammatory response, pain intensity, and the incidence of site-specific complications (such as surgical site infection or seroma)?\n* What is the safety profile of helium-based NTP in the cervical anatomical region regarding neighboring neurovascular structures?\n\nParticipants will be randomized into two arms:\n\n1. The experimental group: Receiving a standardized application of helium-based NTP (at a frequency of 13.56 MHz) to the surgical bed prior to closure and subsequently to the sutured incision.\n2. The control group: Receiving standard-of-care surgical wound management.\n\nClinical follow-up will include quantitative assessment of healing rates, pain scales (VAS), and biochemical or clinical markers of inflammation at scheduled intervals (Days 1, 7, 15, and up to 12 weeks post-surgery).",[535,27,536,141],"Thyroid Diseases","Thyroidectomy",[538,539,540,27,60,541,542],"Non-Thermal Plasma","Cold Plasma","Thyroid Surgery","Adjuvant Therapy","Surgical Bed Decontamination","2026-02-05",{"date":545,"type":34},"2026-02-09",{"date":547,"type":34},"2025-08-20",{"date":82,"type":21},{"name":550,"class":85},"National Institute of Nuclear Research - Mexico",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":557,"enrollmentInfo":558,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":559,"conditions":560,"keywords":565,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":584},"100612144","surgical-critical-care-initiative-sc2i-tissue-and-data-acquisition-protocol-tdap-in-burn-patients-improving-the-robustness-and-generalizability-of-post-burn-sepsis-prediction-with-the-post-burn-sepsis-digital-twin-group-1-100612144","NCT07249762","Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robustness and Generalizability of Post-burn Sepsis Prediction With the Post-Burn Sepsis Digital Twin. Group 1","Inclusion Criteria:\n\n* Burn Injury \\>10% TBSA with who have a recognized concurrent or impending risk for clinical decompensation.\n* Male and female ages 18 years and older (maximum age of 80 years old) with burn injury or related illness requiring surgical care or treatment in a critical care or emergency setting who are being cared for at an SC2i-member clinical care facility (Emory\u002FGrady, USF and USAISR) will be considered for study.\n* Ability to understand the purposes and risks of the study and to provide informed consent, either through written documentation or in accordance with the IRB-approved Waiver of Documentation of Consent procedures. In the case of incapacitated patients, a willing Legally Authorized Representative (LAR) may provide informed consent in accordance with written documentation or under the provisions of the approved Waiver of Documentation of Consent.\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the attending physician, would place the patient or volunteer subject at undue risk by participating. Specific conditions include but are not limited to anemia prohibitive of phlebotomy, or technical considerations that would prevent acquisition of sufficient tissue for clinical use.\n* Pregnant patients\n* Minors \\\u003C 18 years of age\n* Prisoners","80 Years",{"count":482,"type":21},"This study is following adult patients with serious burn injuries to better understand how their bodies respond to treatment and recovery. Researchers will collect small amounts of blood and tissue samples, along with information already recorded in the medical record, such as vital signs, lab results, and details of surgeries or complications. The goal is to identify patterns that may help predict who is at higher risk for infections or other problems after a burn injury. This information could lead to new tools, including computer-based models, to improve burn care and outcomes in the future. Participation involves providing samples and allowing researchers to review medical records during the hospital stay and up to one year after discharge.",[561,562,27,563,564],"Sepsis","Burn Injury","Critical Illness","Multiple Organ Dysfunction Syndrome",[566,561,563,567,568,569,570,27,571,572,573,574],"Burn Infection","Thermal Injury","Infection","Multiple Organ Dysfunction Syndrome (MODS)","Acute Respiratory Distress Syndrome (ARDS)","Biomarkers","Digital Twin Model","Predictive Analytics","Surgical Critical Care","2026-02-02",{"date":577,"type":34},"2026-02-04",{"date":579,"type":21},"2026-05-15",{"date":581,"type":21},"2027-12-15",{"name":583,"class":85},"Henry M. Jackson Foundation for the Advancement of Military Medicine",3,{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":557,"enrollmentInfo":592,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":559,"conditions":594,"keywords":595,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":598,"leadSponsor":599,"locationsCount":584},"100610138","tdap-in-burn-patients-group-2-100610138","NCT07223684","TDAP in Burn Patients (Group 2)","Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robustness and Generalizability of Post-Burn Sepsis Prediction With the Post-Burn Sepsis Digital Twin","Inclusion Criteria:\n\n* Male and female ages 18 years and older (maximum age of 80 years old) with burn injury or related illness requiring surgical care or treatment in a critical care or emergency setting who are being cared for at an SC2i-member clinical care facility (Emory\u002FGrady, USF and USAISR) will be considered for study.\n* Burn Injury \\>10% TBSA\n* Ability to understand the purposes and risks of the study and willingly give written informed consent, or in the case of incapacitated patients, a willing legally authorized representative (LAR) is able to give written informed consent.\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the attending physician, would place the patient or volunteer subject at undue risk by participating. Specific conditions include but are not limited to anemia prohibitive of phlebotomy, or technical considerations that would prevent acquisition of sufficient tissue for clinical use.\n* Pregnant patients\n* Minors \\\u003C 18 years of age\n* Prisoners",{"count":593,"type":21},80,[561,562,27,563,564],[566,561,563,567,568,569,570,27,571,572,573,574],{"date":577,"type":34},{"date":579,"type":21},{"date":581,"type":21},{"name":583,"class":85},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":105,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":22,"phases":609,"briefSummary":610,"conditions":611,"keywords":615,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":42},"100618325","the-effectiveness-of-nano-bio-fusion-gingival-gel-nbf-on-wound-healing-at-the-palate-donor-site-after-soft-tissue-graft-surgery-compared-to-placebo-gel-100618325","NCT07330154","The Effectiveness of Nano Bio Fusion Gingival Gel (NBF) on Wound Healing at the Palate (Donor Site) After Soft Tissue Graft Surgery Compared to Placebo Gel.","The Effectiveness of Nano Bio Fusion Gel (NBF) on Early Wound Healing at the Palate (Donor Site) After Soft Tissue Graft Surgery Compared to Placebo Gel: a Double Blinded Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Patients with gingival recession that is indicated for root coverage or need for phenotype modification.\n2. 18 years or older.\n3. absence of systemic disease\n4. Non-smoker\n5. No use of antibiotics, corticosteroids, anti-inflammatory medication or hormones in the past 3 months\n\nExclusion Criteria:\n\n1. Pregnant or lactating woman.\n2. patients with immune or systemic diseases.\n3. Patients with an allergy to any ingredient in the gel.",{"count":608,"type":21},36,[24],"The goal of this clinical trial is to assess the effect of Nano-biofusion gingival gel (NBF) on wound healing at the palatal donor site following soft tissue graft surgery and compare it to placebo gel. The main questions it aims to answer are:\n\n* Does NBF gel enhance wound healing after graft harvesting from the palate?\n* Does NBF gel reduce the number of inflammatory mediators after surgery?\n* Does NBF gel reduce pain and discomfort at the palatal donor site? Researchers will compare NBF gel to a placebo (a look-alike gel that does not contain the active ingredients) to see if NBF gel enhances wound healing.\n\nStudy steps include:\n\n* Participants will apply the assigned gel on the surgical wound 4 times a day for 4 weeks.\n* Clinical photographs and measurements will be obtained on days (0, 1, 2, 4, 7, 15, 21, 30).\n* Wound fluid samples will be collected on days (0, 1, 2, 4, 7).\n* Participants will be asked about the level of pain and analgesic consumption on each follow-up visit.",[27,612,613,614],"Palatal Wound","Donor Site Complication","Inflammatory Cytokines",[616,117,617,618],"NBF gel","palatal donor site","soft tissue graft","2026-01-21",{"date":621,"type":34},"2026-01-23",{"date":623,"type":34},"2025-10-29",{"date":625,"type":21},"2026-12",{"name":627,"class":85},"King Abdullah University Hospital",{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":105,"sex":51,"minAge":18,"maxAge":634,"enrollmentInfo":635,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":42},"100621558","wound-healing-following-extraction-and-ridge-preservation-in-smokers-and-non-smokers-100621558","NCT07372183","Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers","Inclusion Criteria:\n\n* Adult patients (18-75 years)\n* Good general health (controlled conditions)\n* Smokers (≥10 cigarettes\u002Fday for ≥5 years) and never smokers. Confirmation of smoking status will be done via use of a smokerlyzer. The cut-off point for distinguishing smokers from non-smokers is 8 carbon monoxide parts per million (ppm).\n* Periodontal status: periodontal health, gingivitis on intact or reduced periodontium, treated periodontitis\n* Intact post-extraction bony walls or less than 50% bone dehiscence\n* Distance at least 8 mm of vertical bone height between bone crest and anatomical structures (i.e. sinus floor, inferior alveolar nerve (IAN) canal, mental foramen)\n* Extracted tooth root in the same three-dimensional position as the future implant placement so that the bone core biopsy can be taken from a site totally within the confines of the former tooth socket without inclusion of surrounding native alveolar bone\n* Scheduled for single tooth extraction with bone graft placement and membrane\n\nExclusion Criteria:\n\n* Uncontrolled periodontal disease\n* Uncontrolled systemic disease\n* Pregnancy\n* Use of therapy and\u002For medication that impairs wound healing (e.g., bisphosphonates, steroids, chemotherapy, radiotherapy etc.)","75 Years",{"count":636,"type":21},12,"The goal of this study is to evaluate bone wound healing following extraction and alveolar ridge preservation (bone graft and membrane) clinically, histologically and in relation to gene expression in smokers and non-smokers. Data from a small group of participants will be analyzed after age-matched subjects undergo extraction and alveolar ridge preservation prior to implant placement. The data obtained in this pilot study will be used to plan a full-fledged study involving a larger number of smoking and non-smoking participants to compare the two groups.",[639,640,27,641,642],"Smoking, Cigarette","Alveolar Bone Grafting","Bone Healing","Tooth Extraction Site Healing","2026-01-20",{"date":645,"type":34},"2026-01-28",{"date":647,"type":21},"2026-01-25",{"date":649,"type":21},"2028-10-01",{"name":651,"class":85},"Marquette University",{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":656,"acronym":657,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":51,"minAge":18,"maxAge":659,"enrollmentInfo":660,"targetDuration":4,"studyType":22,"phases":661,"briefSummary":662,"conditions":663,"keywords":4,"overallStatus":151,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":42},"100598720","hydrocolloid-dressings-for-oculofacial-plastic-and-reconstructive-wound-healing-100598720","NCT07075159","Hydrocolloid Dressings for Oculofacial Plastic and Reconstructive Wound Healing","HCD Wound Heal","Inclusion Criteria:\n\n* Patients \\>18 years of age\n* follow-up at specified intervals (1 week\u002F6 week\u002F3 months) in an office setting\n* can give informed consent\n* no patients will be excluded on the basis of gender, ethnicity, or religious background\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age or \\>100\n* allergy to pectin, gelatin, and sodium carboxymethylcellulose\n* adults with impaired consent capacity\n* incarcerated individuals.","100 Years",{"count":379,"type":21},[24],"This study aims to explore the use of a hydrocolloid dressing (DuoDERM EXTRA THIN) as an alternative to the current standard of care. The dressing would be applied immediately after surgery and removed at a post-operative week 1 appointment. The dressing would eliminate the need for antibiotic ointment application and reduce the burden of post-operative care on the patient.",[27,664,665],"Mohs Micrographic Surgery","Oculofacial Reconstruction","2025-12-15",{"date":668,"type":34},"2025-12-17",{"date":670,"type":34},"2025-02-28",{"date":672,"type":21},"2026-09-01",{"name":674,"class":85},"Janice Hernandez, MD"]